TAVR vs. Surgery: A New Look at 1-Year Outcomes Among Moderate-Risk Patients with Severe, Symptomatic AS

Transcatheter aortic valve replacement (TAVR) is not inferior to surgical aortic valve replacement (SAVR) when it comes to all-cause mortality after one year. This is among moderate-risk patients with severe, symptomatic aortic stenosis (AS). According to a new analysis published in JAMA,  a close comparison revealed that each treatment option is associated with certain benefits over the other.